Drugs / VMD-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07636785 | Jun 2026 → May 2031 expected | colorectal cancer, hepatocellular carcinoma, non-small cell lung carcinoma, renal cell carcinoma +1 | VM Discovery, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMD-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07636785 ↗ |
| Action | Inhibit | “first selective PKC epsilon (PKCε or PKCe) kinase inhibitor” NCT07636785 ↗ |
| Modality | Small molecule | “A small organic molecule oral drug in the tablet form” NCT07636785 ↗ |
| Route | Oral | “oral drug” NCT07636785 ↗ |